Verition Fund Management
DNA icon

Verition Fund Management’s Ginkgo Bioworks DNA Stock Holding History

Verition Fund Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,989
Closed -$798K – 2608
2025
Q4 		$798K Sell
95,989
-430
-0.4% -$4.63K ﹤0.01% 2320
2025
Q3 		$1.41M Buy
96,419
+2,265
+2% +$27.1K 0.01% 2266
2025
Q2 		$1.06M Buy
94,154
+100
+0.1% +$775 ﹤0.01% 2430
2025
Q1 		$536K Buy
94,054
+63,527
+208% +$647K ﹤0.01% 2543
2024
Q4 		$300K Sell
30,527
-66,673
-69% -$571K ﹤0.01% 2784
2024
Q3 		$792K Buy
+97,200
New +$974K ﹤0.01% 2048
2023
Q4 		– Sell
-3,398
Closed -$246K – 2412
2023
Q3 		$246K Buy
3,398
+2,385
+235% +$191K ﹤0.01% 1855
2023
Q2 		$75.3K Buy
1,013
+578
+133% +$34.2K ﹤0.01% 2006
2023
Q1 		$23.1K Sell
435
-692
-61% -$43.9K ﹤0.01% 2002
2022
Q4 		$76.2K Sell
1,127
-132
-10% -$12.1K ﹤0.01% 1867
2022
Q3 		$157K Buy
1,259
+75
+6% +$8.94K ﹤0.01% 2542
2022
Q2 		$113K Buy
1,184
+219
+23% +$26.7K ﹤0.01% 2050
2022
Q1 		$155K Buy
965
+215
+29% +$41.8K ﹤0.01% 2389
2021
Q4 		$249K Hold
750
– – ﹤0.01% 2107
2021
Q3 		$348K Buy
+750
New +$365K ﹤0.01% 1397

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's DNA Position: Q1 2026 in Review

Verition Fund Management sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 95,989 shares — an estimated $798K sold.

Verition Fund Management first reported a position in DNA in Q3 2021 and held it in 15 quarters. The position peaked at $1.41M in Q3 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Verition Fund Management reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 95,989 Ginkgo Bioworks shares in Q1 2026, an estimated $798K.
  • Verition Fund Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 15 quarters.
  • Verition Fund Management's Ginkgo Bioworks position peaked at $1.41M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.